MAP17 Orchestrates SGLT2-Dependent Glycolytic Reprogramming to Drive Trained Immunity and Accelerate Atherosclerosis
Arteriosclerosis, Thrombosis, and Vascular Biology · 2026
DOI: 10.1161/atvbaha.126.324585 ↗Kurz gefasst
Fachartikel in der Zeitschrift Arteriosclerosis, Thrombosis, and Vascular Biology, 2026. Verfasst von Jianjin Wu und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Vascular and Endovascular Surgery (J.W., F.Z., F.L., G.F., K.C., K.Z., L.Q.), Second Affiliated Hospital of Naval Medical University, S…. Hauptthemen laut MEDLINE: Glycolysis, Trained Immunity, Macrophages, Atherosclerosis. Die Arbeit nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
BACKGROUND: Atherosclerosis is driven by metabolic-immune crosstalk, in which trained immunity sustains vascular inflammation. MAP17 (membrane-associated protein 17), a redox- and metabolism-regulating adaptor protein, functions as a potential upstream driver of SGLT2 (sodium-glucose cotransporter 2). We aimed to determine whether MAP17 links hyperglycemia to glycolytic activation, inflammatory polarization, and plaque progression in atherosclerosis. METHODS: MAP17 expression and its correlations with clinical risk factors were analyzed in serum from 30 patients with atherosclerosis. A trained immunity model was established in bone marrow–derived macrophages via sustained high glucose and IFN-γ (interferon-γ)/lipopolysaccharide stimulation. Functional assays were performed after MAP17 overexpression/knockdown, SGLT2 silencing, or glycolysis inhibition. RESULTS: MAP17 was significantly coupregulated in patients with atherosclerosis, with the highest levels observed in those with concomitant diabetes or metabolic syndrome, and closely associated with elevated proinflammatory M1-like cytokines. Immunohistochemistry of carotid plaques confirmed its colocalization with SGLT2 within CD68 + macrophage-rich, lipid-laden, and inflamed regions. In bone marrow–derived macrophages, high glucose robustly induced MAP17 expression, which unidirectionally upregulated SGLT2, enhanced glycolytic flux, increased lactate production, and promoted M1-like polarization and foam cell formation. MAP17 knockdown markedly suppressed SGLT2 expression, glycolysis, and TNF-α (tumor necrosis factor-α)/IL (interleukin)-1β secretion, whereas MAP17 overexpression restored glycolytic activity, proinflammatory phenotype, and foam cell generation even in SGLT2-deficient cells. In diabetic chimeric Apoe −/− mice, MAP17 activation correlated with increased glycolytic marker expression, higher proinflammatory M1-like macrophage ratios, aggravated vascular inflammation, and greater plaque burden; these effects were mitigated by MAP17 or SGLT2 silencing, or by glycolysis inhibition. CONCLUSIONS: MAP17 is a key upstream controller of the SGLT2-glycolysis axis that promotes trained immunity and accelerates atherosclerosis. Targeting MAP17 may disrupt the metabolic-inflammatory feedback loop and represents a promising therapeutic strategy for diabetic atherosclerosis.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Vascular and Endovascular Surgery (J.W., F.Z., F.L., G.F., K.C., K.Z., L.Q.), Second Affiliated Hospital of Naval Medical University, Shanghai, China.
- Department of Vascular Surgery, First Affiliated Hospital of Dalian Medical University, China (L.W.).
- Department of Stomatology (H.G.), Second Affiliated Hospital of Naval Medical University, Shanghai, China.
ORCID-Profile: Fukang Zou, Kai Cheng, Haochen Gao, Kangkang Zhi, Lefeng Qu
Zitieren
APA
Wu, J., Wang, L., Zou, F., Liu, F., Fang, G., Cheng, K., Gao, H., Zhi, K., & Qu, L. (2026). MAP17 Orchestrates SGLT2-Dependent Glycolytic Reprogramming to Drive Trained Immunity and Accelerate Atherosclerosis. Arteriosclerosis, Thrombosis, and Vascular Biology. https://doi.org/10.1161/atvbaha.126.324585
Vancouver
Wu J, Wang L, Zou F, Liu F, Fang G, Cheng K, et al. MAP17 Orchestrates SGLT2-Dependent Glycolytic Reprogramming to Drive Trained Immunity and Accelerate Atherosclerosis. Arteriosclerosis, Thrombosis, and Vascular Biology. 2026. doi:10.1161/atvbaha.126.324585
BibTeX
@article{Wu2026,
author = {Wu, Jianjin and Wang, Lei and Zou, Fukang and Liu, Fangbing and Fang, Guanyu and Cheng, Kai and Gao, Haochen and Zhi, Kangkang and Qu, Lefeng},
title = {MAP17 Orchestrates SGLT2-Dependent Glycolytic Reprogramming to Drive Trained Immunity and Accelerate Atherosclerosis},
journal = {Arteriosclerosis, Thrombosis, and Vascular Biology},
year = {2026},
doi = {10.1161/atvbaha.126.324585}
}
EUVIMED